KZIA trade ideas
KZIA Good Risk:Reward RatioKZIA had a very large runup, and a pullback to Higher Low at 0.5637. Expecting a bounce from this level, to scale out of position up above @$1.02; $1.24 and $1.33 levels (Prior swing highs of the leg down). With the minimum risk:reward being 10:1, it is too good of opportunity to miss.
$KZIA looks good for a parabolic runLooks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline.
(1) Price above Kumo
(2) Future Kumo bullish
(3) Senkou span A & B with positive slope
(4) Both Tenkan Sen & Kijun Sen have +ve slopes
(5) Chikou Span above the price & free to go up
(6) ADX > 25
FDA Grants RPDD to Paxalisib for DIPGUS FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
Key Points
With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG
A PRV grants the holder an expedited six-month review of a new drug application by FDA.
PRVs can be sold to other companies and have historically commanded prices between US$68 million and US$350 million
RPDD has been awarded following positive emerging preclinical data in DIPG, and with initial clinical efficacy data expected in 2H CY2020; positive clinical data may substantially enhance likelihood of a potential future PRV
The FDA's RPDD program is intended to advance the development of drugs and biologics for certain serious and life-threatening rare pediatric diseases by providing incentives to industry. Most significant among these incentives is the potential access a priority review voucher at the time of a marketing authorization for the rare paediatric disease.
RPDD may be granted to drugs in development for diseases which primarily affect children (under the age of 18 years), have an incidence of less than 200,000 new cases per annum in the United States, and which are serious or life-threatening.
In effect, the PRV shortens the FDA review period for a future marketing application of any drug from 12 months to 6 months.
finance.yahoo.com
KZIA Leading Diagonal Wave 5 beginsHello,
What is KZIA?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is headquartered in Sydney, Australia.
News
My Thoughts For You
Click on the link "News" and you will find that the outcome is showing positive results which will affect the price.
Good Luck, Cheers!
Be sure to comment, follow, like, and check out my profile for more trade ideas!
KAZIA Therapeutics Ltd Golden CrossCompany profile
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
